Genmab A/S (LON:0MGB)

Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of GBP 12.65 billion. The enterprise value is 10.62 billion.

Market Cap	12.65B
Enterprise Value	10.62B

Important Dates

The next estimated earnings date is Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	61.55M
Shares Outstanding	n/a
Shares Change (YoY)	-3.37%
Shares Change (QoQ)	-3.04%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	60.84M

Valuation Ratios

The trailing PE ratio is 12.64 and the forward PE ratio is 15.31.

PE Ratio	12.64
Forward PE	15.31
PS Ratio	4.75
PB Ratio	3.27
P/TBV Ratio	5.43
P/FCF Ratio	15.89
P/OCF Ratio	15.28
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.70, with an EV/FCF ratio of 13.34.

EV / Earnings	10.62
EV / Sales	3.95
EV / EBITDA	10.70
EV / EBIT	11.29
EV / FCF	13.34

Financial Position

The company has a current ratio of 6.22, with a Debt / Equity ratio of 0.03.

Current Ratio	6.22
Quick Ratio	6.20
Debt / Equity	0.03
Debt / EBITDA	0.11
Debt / FCF	0.14
Interest Coverage	49.22

Financial Efficiency

Return on equity (ROE) is 28.12% and return on invested capital (ROIC) is 15.86%.

Return on Equity (ROE)	28.12%
Return on Assets (ROA)	13.26%
Return on Invested Capital (ROIC)	15.86%
Return on Capital Employed (ROCE)	21.84%
Revenue Per Employee	1.01M
Profits Per Employee	379,165
Employee Count	2,682
Asset Turnover	0.61
Inventory Turnover	21.91

Taxes

In the past 12 months, Genmab has paid 133.43 million in taxes.

Income Tax	133.43M
Effective Tax Rate	11.77%

Stock Price Statistics

The stock price has increased by +0.55% in the last 52 weeks. The beta is 0.80, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	+0.55%
50-Day Moving Average	1,535.54
200-Day Moving Average	1,453.88
Relative Strength Index (RSI)	67.69
Average Volume (20 Days)	12,893

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of GBP 2.66 billion and earned 1.00 billion in profits. Earnings per share was 15.78.

Revenue	2.66B
Gross Profit	2.52B
Operating Income	930.23M
Pretax Income	1.13B
Net Income	1.00B
EBITDA	968.89M
EBIT	930.23M
Earnings Per Share (EPS)	15.78

Balance Sheet

The company has 2.12 billion in cash and 108.03 million in debt, giving a net cash position of 2.01 billion.

Cash & Cash Equivalents	2.12B
Total Debt	108.03M
Net Cash	2.01B
Net Cash Per Share	n/a
Equity (Book Value)	3.87B
Book Value Per Share	62.92
Working Capital	2.39B

Cash Flow

In the last 12 months, operating cash flow was 828.00 million and capital expenditures -31.71 million, giving a free cash flow of 796.29 million.

Operating Cash Flow	828.00M
Capital Expenditures	-31.71M
Free Cash Flow	796.29M
FCF Per Share	n/a

Margins

Gross margin is 94.54%, with operating and profit margins of 34.95% and 37.59%.

Gross Margin	94.54%
Operating Margin	34.95%
Pretax Margin	42.60%
Profit Margin	37.59%
EBITDA Margin	36.40%
EBIT Margin	34.95%
FCF Margin	29.91%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.37%
Shareholder Yield	n/a
Earnings Yield	7.91%
FCF Yield	6.29%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.99 and a Piotroski F-Score of 5.

Altman Z-Score	9.99
Piotroski F-Score	5